Current guidelines advocate for standard HF management, which includes the use of angiotensin-converting enzyme inhibitors (ACEi), sodium-glucose cotransporter-2 (SGLT2) inhibitors, beta-blockers, diuretics, and, in select cases, aldosterone antagonists [2,6,7]. The gene discussed is SLC5A2; the disease is hydrops fetalis.